Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

By K. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, H. Hirte, D. Huntsman, M. Clemons, B. Gilks and 4 more. The Lancet Oncology, 2011

1,094 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/444da6529743916ee7bb729dcf215a51c1eb6e55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

In Reproductive Medicine

Citations in the corpus

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (2012, background): “Cells deficient for BRCA1 or BRCA2 are highly sensitive to PARP1 inhibitors (Bryant et al, 2005; Farmer et al, 2005), which are currently in use in clinical trials for cancer patients with BRCA1 and BRCA2 germline mutations (Gelmon et al, 2011; O’Shaughnessy et al, 2011).”
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, result): “Various studies validated this and extended the usefulness of PARP inhibitors in the treatment setting beyond BRCA-mutated tumours [31, 32].”
Triple-negative breast cancer molecular subtyping and treatment progress (2020, background): “significant difference in response rate between TNBC patients with and without BRCA1/2 mutations [50].”
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas (2013, positive): “Our findings may influence clinical trial design, as most PARPi trials have selected high-grade serous carcinomas as their focus (12).”
PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017, positive): “In HGSOvCa, olaparib was found to reduce the rate of disease recurrence and extend progression-free survival when used as a maintenance therapy in patients previously treated with platinum-based chemotherapy (50–52).”
Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer (2015, background): “Furthermore, in a phase II study of high-grade serous EOC with unknown/nonmutated BRCA status, olaparib was associated with a 24% ORR and a 30% combined RECIST or CA125 response rate (104).”